-
Galloway accuser could not foresee publishing-sector fallout, lawyer argues
-
No. 22 UCLA defeats No. 5 Arizona 84-75 despite Kharchenkov's 38 points
-
New York City Center revives In the Heights as a timely community story
-
Vessel operator seeks witnesses after Vancouver grounding
-
Godzilla Minus Zero shifts focus toward postwar human drama
-
US Air Force deploys F-16 fighters to remote Aleutian base for readiness drill
-
Mehbooba Mufti urges dialogue and renewed Central Asia links for Kashmir
-
Bezos grant helps Seattle nonprofit move thousands of families toward housing
-
Seacliff Healthcare Seeks Specialist GP in Thirroul
-
Shrini Srivastava joins crew of Varanasi-Delhi Vande Bharat Sleeper service
-
US stocks fall before midterm Election Day as technology shares weaken
-
Nearly Half of Australian Workers Overqualified, Survey Finds
-
BLS Polymers makes strong market debut at ₹248 per share
-
RBI eases export-declaration compliance for individual service exporters
-
Petrol and diesel prices remain broadly steady across major Indian cities
-
India proposes more import entry points for drugs and medical devices
-
Reliance shares remain in focus after near-12% surge
-
Derek Tierney Outlines Ten-Year Strategy for National Digital Health System
-
2026 Arizona Midterms: Key Races, Ballot Measures, and Voter Deadlines
-
NBC’s Steve Kornacki Reveals Tech Habits Ahead of Midterm Elections
-
Coal India prepares possible $1 billion Mahanadi Coalfields listing
-
India and Israel oppose UN draft on regional conventional arms control
-
Julia Stiles and Ezra Sosa Share Emotional Farewell After 'DWTS' Elimination
-
BLS Polymers shares open 65.3% above IPO price
-
US Buildings Threatened by Wildfires Could Triple by 2060
-
Capital-markets shares rally as Motilal Oswal and Angel One lead gains
-
Why Pregnancy Cost Estimates Fail: A Family’s $9,000 Surprise
-
Latino Voters Defy ICE Fears, Turn Out in Record Numbers for Midterms
-
US Strikes Iranian Targets in Strait of Hormuz Ahead of Midterms
-
ITC shares rise as analysts anticipate gradual cigarette-business recovery
-
Brodeur’s Overtime Goal Secures Bethlehem’s Second Consecutive Sectional Title
-
Reliance rally puts historical one-year return pattern in focus
-
Rare 1970 Plymouth ‘Cuda 426 Hemi Listed for $400,000
-
Kuwait edges Oman 1-0 in veterans Gulf Cup in Doha
-
The Digital Burden: Why Instant Messaging Feels Like a Full-Time Job
-
Saudi Aramco quarterly profit climbs 34.6% amid elevated oil prices
-
Alberta Tabled Controversial Riding Boundary Maps Amid Gerrymandering Accusations
-
Washington reports movement in Iran negotiations aimed at preventing escalation
-
Hong Kong court set to sentence activist Joshua Wong in security case
-
Korea’s Labor Share of GDP Hits Record Low Amid Semiconductor Boom
-
Australia raises benchmark rate to highest level in 18 years
-
littlefish and Halo Dot Partner to Replace Payment Terminals with SoftPOS
-
'The Remarried Empress' Cast Discusses Bringing Fantasy Royal Drama to Life
-
Kuwait inspectors destroy 115 kilograms of unverified meat in Farwaniya
-
Asian stocks retreat as AI worries outweigh steep oil-price drop
-
Egypt Accelerates Construction of 341km Sinai Railway Linking Arish and Taba
-
Hamad International Airport stages emergency drills during WATAN 2026
-
John Schneider Admits Owes Millions in 'Dukes of Hazzard' Divorce Battle
-
Global failure to punish attacks leaves journalists at continuing risk
-
Philippine Authorities Report Progress in Thomas Markle Sr. Child Pornography Probe
Herbicide under US scrutiny over potential Parkinson's link
First came the slow hand movements, then the tremor, and now the looming fear of what lies ahead.
David Jilbert's devastating diagnosis of Parkinson's disease three years ago changed his life irrevocably -- and it's a condition the 65-year-old farmer believes he wouldn't have if it weren't for paraquat, a herbicide he once relied on to control weeds in his vineyard in the midwestern US state of Ohio.
"Now it's not just about me, I'm part of this community -- let's get something going," Jilbert said during a recent hearing in the US Congress on the issue.
Banned in more than 70 countries -- including Britain, where it is manufactured; Switzerland, home to the Syngenta company that owns the brand; and China, where the state-run conglomerate that owns Syngenta is based -- paraquat remains available in the United States.
The US Environmental Protection Agency (EPA) has long maintained that the herbicide is safe for use under strict regulations -- something Parkinson's advocates are hoping to change.
The agency is set to issue a final report on the issue by January 17, 2025, a date mandated by a court in response to 90 new scientific studies submitted by the Michael J. Fox Foundation and other groups.
- Industry denies causation -
"We have great sympathy for those suffering from the debilitating effects of Parkinson's disease," a spokesperson for Syngenta said in a statement to AFP.
"However, it is important to note that the scientific evidence simply does not support a causal link between paraquat and Parkinson's disease, and that paraquat is safe when used as directed."
Multiple credible studies have found that agricultural workers who handle paraquat -- or live near areas where it is applied -- face a higher incidence of Parkinson's disease, which can eventually turn even the simplest movements into daunting challenges.
Animal research further underscores paraquat's toxic effects on nerve cells, although proving direct causation for individuals remains difficult.
"I find it extraordinarily frustrating that the chemical companies have hidden behind the concept of being able to show causation, and they've used that as an excuse, because we haven't been able to come out and definitively say that," Australia-based neurologist David Blacker said in interview with Pesticide Action UK, an advocacy group.
"That's where the precautionary principle comes in," he added. "If there is a doubt, especially if there are alternatives, it then becomes, in my mind, ethically and even morally unsound to continue to pursue."
- 'It's scary' -
Jilbert, a longtime environmental engineer and environmental safety inspector, dreamed of becoming a farmer after retirement.
In 2011, he purchased his land and, over the following years, began using paraquat -- often sold as Gramoxone -- to manage his weeds. By the end of the decade, he noticed his hands moving slowly and his gait turning into a shuffle.
When his Parkinson's diagnosis finally came, he was horrified and wondered if he'd been condemned to a "death sentence." His condition is more manageable for now, thanks to medications, but he says he feels disappointed in his own government for not looking out for him.
"You think if you use the stuff in the way the label tells me to use it, then I'm not going to get sick," he said.
Like Jilbert, 85-year-old Charlene Tenbrink -- who owns a 250-acre farm in Dixon, California -- also trusted that the chemicals available to farmers were safe when handled properly.
She sprayed paraquat on her prune trees in the 1990s and was diagnosed with Parkinson's in 2020.
Tenbrink, Jilbert and thousands of others are now suing Syngenta in federal and California state courts.
Sarah Doles, a lawyer and co-lead for that federal litigation, compared it to the cases against Big Tobacco. She contends Syngenta had a legal duty to disclose harms its own teams knew about paraquat from research going back decades, but hid from consumers.
"It's a legal duty of what they knew and then failed to do -- they concealed the information," she told AFP.
Regardless of which direction the EPA rules, these legal cases will continue.
Tenbrink says it's vital to get the product off the market, and admits she's terrified for her own future.
"This is a terrible disease and we know there's no cure, we know it's going to get worse. It's scary," she says.
T.Perez--AT